knowledge -WSS

knowledge

author：comprehensive 2025-09-29 02:46:45 - browse：29417

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： California’s proposed $25 per hour health care minimum wage

WSS

Retired US general questions alleged Putin, Prigozhin meeting

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

5 ways to address the shortage of health care workers

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Pfizer is about to make a big push in cancer. Will investors listen?

entertainment

knowledge

explore

Affirmative action in medical school literally saved lives

Color Health wants to make cancer screenings convenient

Psychedelics group wrestles with new pharma identity

Virtual repurposing can help discover new uses for existing drugs

Drug repurposing or repositioning? The language matters

Petition to FDA: Get the lead out of consumer hair dyes

Dobbs anniversary: the lost opportunity of abortion as health care

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Palantir health business leans on meeting customers’ needs

hotspot

NEJM study measures Covid brain fog, impact on IQ

Iowa House, Senate pass 6

Study: Pain burden is higher in Black NFL players than white ones

Palantir health business leans on meeting customers’ needs

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

A new study sees potential in DNA sequencing of infants

hotspot

Wikipedia

knowledge

leisure time